Company attributes
Other attributes
Rani Therapeutics is biotherapeutics company based in San Jose, California and was founded in 2012 by Mir Imran. It develops novel approaches for the oral delivery of peptides, proteins, and therapeutic antibodies that can normally only be delivered through injections. The approach and technology for Rani Therapeutics was developed at InCube Labs, a multidisciplinary R&D lab focused on developing medical innovations.
It's main product, Rani's 'robotic' pill is a device which navigates through the stomach and enters the small intestine. The capsule then goes through a transformation and aligns itself and injects the drug into the intestinal wall.
Rani has identified several potential molecules to be used with the RaniPill:
- Ocreotide - lowers levels of excess growth hormones for the treatment of acromegaly, a disorder characterized by enlargement of face, hands, and feet.
- Basal Insulin - used in diabetes management as a way to regulate glucose levels in between meals.
- GLP-1 - a class of drugs used in the treatment of Type II diabetes and obesity.
- Parathyroid Hormone (PTH) - commonly used for the treatment of osteoporosis, PTH increases the concentration of calcium in the blood by acting upon the parathyroid hormone 1 & 2 receptor.
- Human Growth Hormone (HGH) - a peptide hormone that stimulates growth, cell reproduction, and regeneration, and is used in the treatment of growth disorders and growth deficiency.
- Human Interferon beta-1a - a cytokine or small protein in the interferon family used for the treatment of multiple sclerosis.
- TNF-alpha (TNFa) Inhibitors - suppresses response to tumor necrosis factor, part of the inflammatory response. Used to treat a number of inflammatory disorders including rheumatoid arthritis and Crohn's disease.
- Interleukin Antibodies - various antibodies targeting specific interleukins for the treatment of various inflammatory diseases, such as rheumatoid arthritis, Chrohn's disease, and psoriasis.
- PCSK9 - a treatment for cardiovascular disease that is often used with other therapies like statins to lower low-density lipoprotein cholesterol (LDL-C) for patients with hyperlipidemia.
- Factor VIII, Factor IX, Factor X - treatments of blood clotting disorders, including Hemophilia A and B.
On June 13, 2012 Rani Therapeutics completed their series A funding round with $4 million in funding from InCube Ventures.
On July 28, 2013 Rani Therapeutics completed their series B funding round with $9.4 million in funding from Google Ventures (lead investor) and InCube Ventures.
On May 26, 2015 Rani Therapeutics completed their series C funding round with $37.5 million in funding from Western Life Sciences Venture Fund, VentureHealth, The Stevanato Group, Pinemount Investment, Pacific Venture Opportunity Fund, Novartis, InCube Ventures, Google Ventures, and Crystal Horizon Investments.
On September 9, 2017 Rani Therapeutics completed their series D funding round with $39 million in funding from Google Ventures (lead investor), Novartis, and AstraZeneca.
On February 7, 2018 Rani Therapeutics completed a venture funding round with $53 million in funding from Shire (lead investor), GeneScience Pharmaceuticals (lead investor), Cathey Venture (lead investor), Bossa Ventures (lead investor), Virtus Inspire Ventures, Ping An Ventures, Google Ventures, and AstraZeneca.
